4D Molecular Therapeutics, Inc. (FDMT) company profile
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
About 4D Molecular Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
4D Molecular Therapeutics is a clinical-stage biotechnology company that develops disease-targeted genetic medicines. The company engineers therapies using its proprietary Therapeutic Vector Evolution platform, which creates customized adeno-associated virus vectors. Its development pipeline centers on clinical-stage therapeutic candidates for retinal and lung conditions. The lead candidate, 4D-150, targets retinal vascular diseases by delivering biologics that inhibit vascular endothelial growth factors. Additional pipeline programs include 4D-175, 4D-710, and 4D-725. The company works with collaboration partners, including Otsuka Pharmaceutical and the Cystic Fibrosis Foundation, to develop treatments for patients.
The company is headquartered in Emeryville, California, where it leases office, laboratory, and warehouse facilities. It is incorporated in Delaware and conducts operations and clinical development primarily within the United States, alongside collaborative partnerships extending to Japan.
Summary of the business section of 4D Molecular Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 4D Molecular Therapeutics, Inc.
- Founded
- 2013
- Headquarters
- Emeryville, CA
- Address
- 5858 Horton Street #455 94608
- Phone
- (510) 505-2680
- Website
- 4dmoleculartherapeutics.com
- Employees
- 196, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- FDMT
- Exchange
- Nasdaq
- IPO date
- Dec 14, 2020
- Shares outstanding
- 72M, Aug 10, 2026
- Public float
- $166.46M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1650648
- CUSIP
- 35104E100
- ISIN
- US35104E1001
- FIGI
- BBG00QG40R88
- Share class FIGI
- BBG00QG40S04
- EIN
- 47-3506994
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Kirn | See Remarks, Director | 1,309,153 |
| Scott Bizily | Chief Legal Officer | 8,617 |
| Christopher Paul Simms | See Remarks | – |
| Ashoo Gupta | VP, Finance and Controller | 47,055 |
| Kristian Humer | Chief Financial Officer | – |
| Robert Young Kim | Chief Medical Officer | 1,595 |
| Uneek Mehra | See Remarks | – |
| Fariborz Kamal | President & COO | 4,347 |
| Susannah Gray | Director | – |
| John F. Milligan | Director | 100,000 |
| Shawn Tomasello | Director | – |
| Nancy Miller-Rich | Director | – |
| Glenn Sblendorio | Director | – |
| Charles Theuer | Director | 41,684 |
| Jacob Chacko | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.05M | $3.29M | $2.72M | $34 | – |
| FY2024 | $1.01M | -$6.84M | $779.25K | $25 | – |
| FY2023 | $10.29M | $15.35M | $4.25M | $91 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| David Kirn, M.D. President and Chief Executive Officer | $667.25K | – | $822.75K | $560.60K | $744 | $2.05M | +103% |
| Kristian Humer Chief Financial Officer | $66.00K | $50.00K | $3.87M | – | $247 | $3.99M | – |
| Fariborz Kamal, Ph.D. Former Chief Operating Officer & President | $551.74K | – | $548.71K | $339.51K | $1.61K | $1.44M | +96% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 14, 2020
- Offer price
- $23.00
- Securities offered
- 8,400,000
- Gross proceeds
- $193.20M
- Exchange
- Nasdaq
- First trading day
- Dec 11, 2020
- First-day close
- $40.50+76.1%
- Lock-up ends (est.)
- Jun 9, 2021
“The initial public offering price is $23.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 6, 2026, we had 196 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 14, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 8, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?